| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978594 | Bulletin du Cancer | 2013 | 6 Pages |
Abstract
Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Richard Lemal, Marie Robin, Aurélie Ravinet, Victoria Cacheux, Romain Guièze, Jacques-Olivier Bay,